Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSP191 as Second-line Therapy in LR-MDS
NCT05903274Phase 1Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of briquilimab in myelodysplastic syndrome (MDS), sponsored by Jasper Therapeutics, Inc. Primary endpoint: Safety and tolerability of JSP191 at 32 weeks. Started Jun 2023; status: terminated.
02
Drugs
briquilimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05903274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903274.